XLRN Acceleron Pharma Inc.

26.64
0  -1%
Previous Close 26.85
Open 26.96
Price To book 4.55
Market Cap 1.02B
Shares 38,394,000
Volume 204,842
Short Ratio 8.31
Av. Daily Volume 409,007

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 2H 2017.
ACE-083
Charcot-Marie-Tooth disease (CMT)
Phase 2 updated data at ASH 2016.
Luspatercept
Low or intermediate-risk MDS patients who are erythropoiesis-stimulating agent (ESA) naïve or ring sideroblast negative (RS-)
Phase 3 enrollment to be completed 2H 2017.
Luspatercept - MEDALIST
Myelodysplastic syndromes (MDS) cancer
Phase 3 enrollment to be completed 2H 2017.
Luspatercept - BELIEVE
b -thalassemia
Phase 2 dosing initiation announced December 22, 2016. Open label initial data due late 2017, with randomized part of trial to be initiated in 2018.
ACE-083
Facioscapulohumeral muscular dystrophy
Phase 2 preliminary data due 2H 2017.
Dalantercept - DART Study
Renal Cell Carcinoma (RCC) - cancer

Latest News

  1. Acceleron Announces Plans to Initiate a Phase 2 Trial of ACE-083 in Charcot-Marie-Tooth Neuromuscular Disease and Host Educational Webinar
  2. Coverage initiated on Acceleron Pharma by JP Morgan
  3. ACCELERON PHARMA INC Financials
  4. Acceleron Pharma, Inc. :XLRN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 3, 2017
  5. Acceleron Pharma Price Target Raised by Leerink
  6. Acceleron Pharma Inc Earnings Call scheduled for 8:00 am ET today
  7. Acceleron reports 4Q loss
  8. Acceleron reports 4Q loss
  9. ACCELERON PHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
  10. Q4 2016 Acceleron Pharma Inc Earnings Release - Before Market Open
  11. Acceleron Reports Fourth Quarter and Year Ended 2016 Operational and Financial Results
  12. Acceleron to Participate in Two Healthcare Investor Conferences in March
  13. Acceleron Pharma to Webcast Conference Call of Fourth Quarter and Year Ended 2016 Financial Results on March 1, 2017
  14. Acceleron to Participate in Two Healthcare Investor Conferences in February
  15. ACCELERON PHARMA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  16. Top Insider Buys Highlight for Week of Jan. 6
  17. Acceleron Outlines Corporate Goals and Priorities for 2017
  18. Acceleron Outlines Corporate Goals and Priorities for 2017
  19. Former CEO of Finish Line Inc. (FINL) Sells Shares as Underperformance Persists; Other Notable Insider Transactions
  20. Acceleron to Webcast Presentation at 35th Annual J.P. Morgan Healthcare Conference